Valneva SE (NASDAQ:VALN) Short Interest Update

Valneva SE (NASDAQ:VALN) saw a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 22,900 shares, a growth of 44.0% from the December 31st total of 15,900 shares. Based on an average daily volume of 41,600 shares, the short-interest ratio is currently 0.6 days. Currently, 0.0% of the shares of the company are short sold.

Institutional Investors Weigh In On Valneva

An institutional investor recently raised its position in Valneva stock. AlphaCentric Advisors LLC grew its position in shares of Valneva SE (NASDAQ:VALN) by 33.7% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 118,000 shares of the company’s stock after buying an additional 29,748 shares during the quarter. AlphaCentric Advisors LLC owned 0.15% of Valneva worth $717,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 11.39% of the company’s stock.

Valneva Stock Performance

Valneva stock traded up $0.53 during mid-day trading on Friday, reaching $5.78. 64,274 shares of the company were exchanged, compared to its average volume of 36,012. The firm has a market cap of $469.68 million, a PE ratio of -44.46 and a beta of 1.93. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78. The firm’s 50-day simple moving average is $4.35 and its two-hundred day simple moving average is $5.70. Valneva has a twelve month low of $3.62 and a twelve month high of $9.50.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Valneva in a research note on Friday.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.